One To Watch

Iterum Therapeutics

A clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.

Iterum is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation and IV formulation.

Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Iterum has received Qualified Infectious Disease Product and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Want to Update your Company's Profile?